	US 12,419,949 B2
	Modified human cytomegalovirus proteins
Marco Biancucci, Rockville, MD (US); Sumana Chandramouli, Rockville, MD (US); and Newton Muchugu Wahome, Rockville, MD (US)
Assigned to GLAXOSMITHKLINE BIOLOGICALS SA, Rixensart (BE)
Appl. No. 17/628,351
Filed by GLAXOSMITHKLINE BIOLOGICALS SA, Rixensart (BE)
PCT Filed Jul. 22, 2020, PCT No. PCT/IB2020/056913 § 371(c)(1), (2) Date Jan. 19, 2022, PCT Pub. No. WO2021/014385, PCT Pub. Date Jan. 28, 2021.
Claims priority of provisional application 62/877,888, filed on Jul. 24, 2019.
Prior Publication US 2023/0201334 A1, Jun. 29, 2023
Int. Cl. A61K 39/245 (2006.01); C07K 14/005 (2006.01)

CPC A61K 39/245 (2013.01) [C07K 14/005 (2013.01)]

14 Claims

1. A modified human cytomegalovirus (HCMV) glycoprotein B (gB) protein comprising a trimerization domain operably linked c-terminal to the residue corresponding to 724 numbered according to SEQ ID NO: 1, wherein an amino acid linker is between the residue corresponding to 724, numbered according to SEQ ID NO: 1, and the trimerization domain, wherein the trimerization domain is a GCN4 Leucine Zipper (GCN4) domain, and wherein the modified HCMV gB protein is in pre-fusogenic conformation, and wherein the modified HCMV gB protein comprises a proline substitution of one or more residues corresponding to N478-R511 numbered according to SEQ ID NO: 1.